Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Sternberg

Showing results (491-500 of 564) with videos related to

Pageof 57
Sort By:
Future Oncology (London, England)|November 24, 2025
A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tractThomas Powles, Scott T Tagawa, Christof Vulsteke, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2013
Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohortRoberto Iacovelli, Giacomo Cartenì, Cora N Sternberg, et al.
Frontiers in Oncology|December 5, 2018
Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC DatabaseGabriella Del Bene, Fabio Calabrò, Diana Giannarelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2019
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-upY Fradet, J Bellmunt, D J Vaughn, et al.
Cancers|July 29, 2025
Blood-Epigenetic Biomarker Associations with Tumor Immunophenotype in Patients with Urothelial Carcinoma from JAVELIN Bladder 100Thomas Powles, Srikala S Sridhar, Joaquim Bellmunt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2024
Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial CancerYohann Loriot, Arjun V Balar, Daniel P Petrylak, et al.
European Urology Focus|June 5, 2024
Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract CarcinomaCora N Sternberg, Yohann Loriot, Ernest Choy, et al.
Nature Communications|December 4, 2020
Common germline-somatic variant interactions in advanced urothelial cancerAram Vosoughi, Tuo Zhang, Kyrillus S Shohdy, et al.
European Urology Oncology|August 15, 2019
Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract CancersNieves Martinez Chanza, Lillian Werner, Elizabeth Plimack, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2023
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate CancerSusan Halabi, Qian Yang, Akash Roy, et al.
Pageof 57

Showing results (491-500 of 564) with videos related to

Sort By:
Pageof 57
Future Oncology (London, England)|November 24, 2025
A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tractThomas Powles, Scott T Tagawa, Christof Vulsteke, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2013
Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohortRoberto Iacovelli, Giacomo Cartenì, Cora N Sternberg, et al.
Frontiers in Oncology|December 5, 2018
Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC DatabaseGabriella Del Bene, Fabio Calabrò, Diana Giannarelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2019
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-upY Fradet, J Bellmunt, D J Vaughn, et al.
Cancers|July 29, 2025
Blood-Epigenetic Biomarker Associations with Tumor Immunophenotype in Patients with Urothelial Carcinoma from JAVELIN Bladder 100Thomas Powles, Srikala S Sridhar, Joaquim Bellmunt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2024
Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial CancerYohann Loriot, Arjun V Balar, Daniel P Petrylak, et al.
European Urology Focus|June 5, 2024
Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract CarcinomaCora N Sternberg, Yohann Loriot, Ernest Choy, et al.
Nature Communications|December 4, 2020
Common germline-somatic variant interactions in advanced urothelial cancerAram Vosoughi, Tuo Zhang, Kyrillus S Shohdy, et al.
European Urology Oncology|August 15, 2019
Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract CancersNieves Martinez Chanza, Lillian Werner, Elizabeth Plimack, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2023
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate CancerSusan Halabi, Qian Yang, Akash Roy, et al.
Pageof 57